<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450813</url>
  </required_header>
  <id_info>
    <org_study_id>COVMOPR0176</org_study_id>
    <nct_id>NCT01450813</nct_id>
  </id_info>
  <brief_title>The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy</brief_title>
  <official_title>The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Bispectral Index monitor is used in many operating rooms to provide information to the
      anesthesiologist about a patient's level of consciousness. The Composite Variability Index,
      or Composite Variability Index (CVI), is a new index that may provide the anesthesiologist
      with more information about the condition of the patient. The purpose of this study is to
      determine if a commonly used anesthetic drug (rocuronium) affects the CVI measurement
      differently with different doses. Rocuronium is a muscle relaxant routinely used during
      surgery. It is expected that the group given the highest dose of rocuronium will have
      diminished CVI values.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will randomize patients to one of four doses of rocuronium: no rocuronium, 0.2,
      0.4, and 0.6 milligrams per kilo of body weight; the last dose is the standard amount for
      adults. It is expected that the group given the highest dose of rocuronium will have
      diminished CVI values. By including intermediate doses, information about the function of
      CVI in states of less than full muscle relaxation, or paralysis, will be obtained. This
      information is critically important for the development of the composite variability index,
      because during general anesthesia patients are usually maintained in a state of less than
      full paralysis. If the CVI response to stimulation in the intermediate groups is similar to
      the group receiving no rocuronium, the monitor may find wide clinical applicability. If the
      response is similar to the maximal rocuronium group, the index may only be reliable in
      states with no muscle relaxant, which will greatly limit clinical utility.

      Subjects will receive propofol and remifentanil infusions during the case. These are
      commonly used medications for anesthesia. The subjects will also be randomized to two
      additional groups. One group will receive a remifentanil infusion of 2ng ml-1 and the other
      group will receive a 8ng ml-1 remifentanil infusion. Both doses are acceptable and often
      used during standard clinical care. The propofol infusion will be adjusted to keep the BIS
      number between 45-60. The anesthesiologist will not be able to see the CVI value. The times
      of certain intraoperative events, such as intubation and incision, will be recorded. All
      subjects will receive a morphine bolus (0.10-0.15 mg/kg) towards the end to reduce
      post-operative pain, as per standard clinical care. As the subject wakes up, time to eye
      opening and orientation will be recorded. The subject will rate their pain on a numerical
      pain scale and the quality of emergence will be assessed.

      Upon arrival in the post anesthesia care unit (PACU), subjects will be asked to rate their
      pain again using the same pain scale. The pain score will be evaluated every 10 minutes for
      half an hour, then every hour until they are discharged from PACU.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between the mean CVI value prior to laryngoscopy to the maximal CVI reading following laryngoscopy.</measure>
    <time_frame>The mean CVI value in the three minutes prior to laryngoscopy will be compared to the maximal CVI reading during the three minutes following laryngoscopy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The average CVI level during the maintenance phase of surgery.</measure>
    <time_frame>The maintenance phase is defined as the time from surgical incision to the time that the propofol is turned off.</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Anesthesia</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Dose 1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0 mg/kg + Remifentanil infusion of 2ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0.2 mg/kg + Remifentanil infusion of 2ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0.4 mg/kg + Remifentanil infusion of 2ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0.6 mg/kg + Remifentanil infusion of 2ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0 mg/kg + Remifentanil infusion of 8ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0.2 mg/kg + Remifentanil infusion of 8ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0.4 mg/kg + Remifentanil infusion of 8ng ml-1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dose 0.6 mg/kg + Remifentanil infusion of 8ng ml-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1a</intervention_name>
    <description>Rocuronium dose 0 mg/kg + Remifentanil infusion of 2ng ml-1</description>
    <arm_group_label>Dose 1a</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2a</intervention_name>
    <description>Rocuronium dose 0.2 mg/kg + Remifentanil infusion of 2ng ml-1</description>
    <arm_group_label>Dose 2a</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 3a</intervention_name>
    <description>Rocuronium dose 0.4 mg/kg + Remifentanil infusion of 2ng ml-1</description>
    <arm_group_label>Dose 3a</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 4a</intervention_name>
    <description>Rocuronium dose 0.6 mg/kg + Remifentanil infusion of 2ng ml-1</description>
    <arm_group_label>Dose 4a</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 1b</intervention_name>
    <description>Rocuronium dose 0 mg/kg + Remifentanil infusion of 8ng ml-1</description>
    <arm_group_label>Dose 1b</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 2b</intervention_name>
    <description>Rocuronium dose 0.2 mg/kg + Remifentanil infusion of 8ng ml-1</description>
    <arm_group_label>Dose 2b</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 3b</intervention_name>
    <description>Rocuronium dose 0.4 mg/kg + Remifentanil infusion of 8ng ml-1</description>
    <arm_group_label>Dose 3b</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose 4b</intervention_name>
    <description>Rocuronium dose 0.6 mg/kg + Remifentanil infusion of 8ng ml-1</description>
    <arm_group_label>Dose 4b</arm_group_label>
    <other_name>Rocuronium bromide: Zemuron</other_name>
    <other_name>Remifentanil: Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of ASA physical status class I or II. (This will exclude subjects with
             significant medical problems).

          -  Body mass index between 18 and 35 kg m-2.

          -  No use of psychotropic or neuropsychiatric medications.

          -  A airway assessment with no indication of a difficult intubation including a class I
             or II Mallampati airway and a mandible-to-hyoid distance of greater than three
             fingerbreadths.

          -  Age between 18-75 years.

        Exclusion Criteria:

          -  Does not meet inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald M Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 2, 2015</lastchanged_date>
  <firstreceived_date>September 22, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
